Adcock Ingram aborts bid to acquire Cipla Medpro
This article was originally published in Scrip
Adcock Ingram has aborted its bid to acquire Cipla Medpro South Africa (CMSA) in view of the lack of response from the CMSA board and concerns about what Cipla India might do – the latter has a commercial relationship with CMSA.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…